nach oben

Erschienen in:

01.07.2007 | Original Article

Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins

verfasst von: Attaphol Pawarode, Suneet Shukla, Hans Minderman, Stacy M. Fricke, Elaine M. Pinder, Kieran L. O’Loughlin, Suresh V. Ambudkar, Maria R. Baer

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 2/2007

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We sought to determine the effects of the immunosuppressants, cyclosporin A (CsA), tacrolimus and sirolimus, on drug transport by the ATP-binding cassette proteins, P-glycoprotein (Pgp; ABCB1), multidrug resistance protein-1 (MRP-1; ABCC1) and breast cancer resistance protein (BCRP; ABCG2), and the major vault protein lung resistance protein (LRP).

Methods

Cellular content of mitoxantrone, a Pgp, MRP-1 and BCRP substrate, was measured by flow cytometry in cells overexpressing these proteins following incubation with and without CsA, tacrolimus or sirolimus. Interaction of BCRP with these compounds was studied by photolabeling and ATPase assays. Nuclear–cytoplasmic distribution of doxorubicin was studied by confocal microscopy in cells overexpressing LRP.

Results

CsA increased cellular drug uptake in cells overexpressing Pgp, MRP-1 or BCRP and nuclear drug uptake in cells overexpressing LRP at the clinically achievable concentration of 2.5 μM. Tacrolimus enhanced cellular drug uptake at 1 μM, but not at 0.08 μM, its clinically achievable concentration, and did not enhance nuclear drug uptake. Sirolimus enhanced cellular drug uptake in cells overexpressing Pgp, MRP-1 and BCRP with optimal effects at 2.5 μM, but was effective at its clinically achievable concentration of 0.25 μM if cells were pre-incubated for at least 30 min before drug exposure, and also enhanced nuclear drug uptake at 0.25 μM. BCRP modulation by all three immunosuppressive agents was associated with competitive binding to the drug transport sites.

Conclusions

CsA, tacrolimus and sirolimus modulate drug transport by Pgp, MRP-1 and BCRP and CsA and sirolimus modulate drug transport by LRP at concentrations that differ from immunosuppressive concentrations and maximum tolerated concentrations.

Ambudkar SV (1998) Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells. Methods Enzymol 292:504–514PubMedCrossRef

Arceci RJ, Stieglitz K, Bierer BE (1992) Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. Blood 80:1528–1536PubMed

Baer MR, George SL, Dodge RK, O’Loughlin KL, Minderman H, Caligiuri MA, Anastasi J, Powell BL, Kolitz JE, Schiffer CA, Bloomfield CD, Larson RA (2002) Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 100:1224–1232PubMed

Benderra Z, Faussat AM, Sayada L, Perrot JY, Chaoui D, Marie JP, Legrand O (2004) Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin Cancer Res 10:7896–7902PubMedCrossRef

van den Berg AP, van Son WJ, Haagsma EB, The TH, Slooff MJ, de Leij LM (2001) Prediction of the inhibition of IL-2 production by calcineurin inhibitors. Transplant Proc 33:1076–1077PubMedCrossRef

Borgnia MJ, Eytan GD, Assaraf YG (1996) Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem 271:3163–3171PubMedCrossRef

Brattstrom C, Sawe J, Tyden G, Herlenius G, Claesson K, Zimmerman J, Groth CG (1997) Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients. Ther Drug Monit 19:397–406PubMedCrossRef

Chan S (2004) Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 91:1420–1424PubMedCrossRef

Chen ZS, Aoki S, Komatsu M, Ueda K, Sumizawa T, Furukawa T, Okumura H, Ren XQ, Belinsky MG, Lee K, Kruh GD, Kobayashi M, Akiyama S (2001) Reversal of drug resistance mediated by multidrug resistance protein (MRP) 1 by dual effects of agosterol A on MRP1 function. Int J Cancer 93:107–113PubMedCrossRef

10.

Ejendal KF, Hrycyna CA (2005) Differential sensitivities of the human ATP-binding cassette transporters ABCG2 and P-glycoprotein to cyclosporin A. Mol Pharmacol 67:902–911PubMedCrossRef

11.

Ferron GM, Mishina EV, Zimmerman J, Jusko W (1997) Population pharmacokinetics of sirolimus in kidney transplant patients. Clin Pharmacol Ther 61:416–428PubMedCrossRef

12.

Friedman J, Weissman I (1991) Two cytoplasmic candidates for immunophilin action are revealed by affinity for a new cyclophilin: one in the presence and one in the absence of CsA. Cell 66:799–806PubMedCrossRef

13.

Garcia-Escarp M, Martinez-Munoz V, Sales-Pardo I, Barquinero J, Domingo JC, Marin P, Petriz J (2004) Flow cytometry-based approach to ABCG2 function suggests that the transporter differentially handles the influx and efflux of drugs. Cytometry A 62:129–138PubMedCrossRef

14.

Goldberg H, Ling V, Wong PY, Skorecki K (1988) Reduced cyclosporin accumulation in multidrug-resistant cells. Biochem Biophys Res Commun 152:552–558PubMedCrossRef

15.

Gummert JF, Ikonen T, Morris RE (1999). Newer immunosuppressive drugs: a review. J Am Soc Nephrol 10:1366–1380PubMed

16.

Gupta A, Dai Y, Vethanayagam RR, Hebert MF, Thummel KE, Unadkat JD, Ross DD, Mao Q (2006) Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer Chemother Pharmacol 58:374–383PubMedCrossRef

17.

Hamilton G, Muhlbacher F, Roth E, Wolf I, Piza F, Havel M, Laczkovics A, Schindler J, Wolosczuk W. (1987) Comparison of cyclosporine A dosage and metabolism in liver and heart transplant recipients. Transplant Proc 19:1706–1708PubMed

18.

Heidecke CD, Nicolaus C, Stadler J, Florack G, Bollschweiler E, Holscher M (1987) Measurement of cyclosporine bioactivity in serum of renal transplant recipients: development and comparison with RIA. Transplant Proc 19:1734–1736PubMed

19.

Honjo Y, Hrycyna CA, Yan QW, Medina-Perez WY, Robey RW, van de Laar A, Litman T, Dean M, Bates SE (2001) Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 61:6635–6639PubMed

20.

Johnson EM, Zimmerman J, Duderstadt K, Chambers J, Sorenson AL, Granger DK (1996) A randomized, double-blind, placebo controlled study of the safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus in stable renal transplant recipients. Transplant Proc 28:987PubMed

21.

Kahan BD (1985) Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters. Transplantation 40:457–476PubMedCrossRef

22.

Legrand O, Simonin G, Perrot JY, Zittoun R, Marie JP (1998) Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood 91:4480–4488PubMed

23.

Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, Head DR, Appelbaum FR, Willman CL (1997) Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 89:3323–3329PubMed

24.

Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS, Head DR. Weick J, Grever MR, Appelbaum FR, Willman CL (1999) Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group study. Blood 94:1086–1099PubMed

25.

List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W (1993) Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 11:1652–1660PubMed

26.

List AF, Spier CS, Grogan TM, Johnson C, Roe DJ, Greer JP, Wolff SN, Broxterman HJ, Scheffer GL, Scheper RJ, Dalton WS (1996) Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 87:2464–2469PubMed

27.

List AF, Kopecky KJ, Willman CL, Head DR, Persons DL, Slovak ML, Dorr R, Karanes C, Hynes HE, Doroshow JH, Shurafa M, Appelbaum FR (2001) Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 98:3212–3220PubMedCrossRef

28.

Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL (1991) Calcineurin is a common target of cyclophilin–cyclosporin A and FKBP–FK-506 complexes. Cell 66:807–815PubMedCrossRef

29.

Maki N, Moitra K, Silver C, Ghosh P, Chattopadhyay A, Dey S (2006) Modulator-induced interference in functional cross talk between the substrate and the ATP sites of human P-glycoprotein. Biochemistry 45:2739–2751PubMedCrossRef

30.

Minderman H, Suvannasankha A, O’Loughlin KL, Scheffer GL, Scheper RJ, Robey RW, Baer MR (2002) Flow cytometric analysis of breast cancer resistance protein expression and function. Cytometry 48:59–65PubMedCrossRef

31.

Mogi M, Yang J, Lambert JF, Colvin GA, Shiojima I, Skurk C, Summer R, Fine A, Quesenberry PJ, Walsh K (2003) Akt signaling regulates side population cell phenotype via Bcrp1 translocation. J Biol Chem 278:39068–39075PubMedCrossRef

32.

Nguyen H, Zhang S, Morris ME (2003) Effect of flavonoids on MRP1-mediated transport in Panc-1 cells. J Pharm Sci 92:250–257PubMedCrossRef

33.

Ozvegy C, Litman T, Szakacs G, Nagy Z, Bates S, Varadi A, Sarkadi B (2001) Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun 285:111–117PubMedCrossRef

34.

Product Information: Rapamune(R), sirolimus. Wyeth Laboratories, Division of Wyeth-Ayerst Pharmaceuticals Inc. Philadelphia, PA, (PI revised 01/2001), reviewed 03/2001

35.

Qadir M, O’Loughlin K, Williamson NA, Fricke SM, Minderman H, Baer MR (2005) Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clin Cancer Res 11:2320–2326PubMedCrossRef

36.

Rogers AJ, Yoshimura N, Kerman RH, Kahan BD (1984) Immunopharmacodynamic evaluation of cyclosporine-treated renal allograft recipients. Transplantation 38:657–664PubMedCrossRef

37.

Sauna ZE, Smith MM, Muller M, Kerr KM, Ambudkar SV (2001) Mechanism of action of multidrug-resistance-linked P-glycoprotein. J Bioenerg Biomembr 33:481–491PubMedCrossRef

38.

Schaich M, Soucek S, Thiede C, Ehninger G, Illmer T (2005) MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. Br J Haematol 128:324–332PubMedCrossRef

39.

Schreiber SL (1991) Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 251:283–287PubMedCrossRef

40.

Scott LJ, McKeage K, Keam SJ, Plosker GL (2003) Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 63:1247–1297PubMedCrossRef

41.

Sharom FJ, Lu P, Liu R, Yu X (1998) Linear and cyclic peptides as substrates and modulators of P-glycoprotein: peptide binding and effects on drug transport and accumulation. Biochem J 333:621–630PubMed

42.

Shukla S, Robey RW, Bates SE, Ambudkar SV (2006) The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2. Biochemistry 45:8940–8951PubMedCrossRef

43.

Slovak ML, Ho JP, Cole SP, Deeley RG, Greenberger L, de Vries EG, Broxterman HJ, Scheffer GL, Scheper RJ (1995) The LRP gene encoding a major vault protein associated with drug resistance maps proximal to MRP on chromosome 16: evidence that chromosome breakage plays a key role in MRP or LRP gene amplification. Cancer Res 55:4214–4219PubMed

44.

Steinbach D, Sell W, Voigt A, Hermann J, Zintl F, Sauerbrey A (2002) BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia 16:1443–1447PubMedCrossRef

45.

Suvannasankha A, Minderman H, O’Loughlin KL, Nakanishi T, Greco WR, Ross DD, Baer MR (2004) Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function. Leukemia 18:1252–1257PubMedCrossRef

46.

Takada T, Suzuki H, Gotoh Y, Sugiyama Y (2005) Regulation of the cell surface expression of human BCRP/ABCG2 by the phosphorylation state of Akt in polarized cells. Drug Metab Dispos 33:905–909PubMedCrossRef

47.

Zimmerman J, Kahan BD (1997) Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol 37:405–415PubMed

Titel: Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins
verfasst von: Attaphol Pawarode
Suneet Shukla
Hans Minderman
Stacy M. Fricke
Elaine M. Pinder
Kieran L. O’Loughlin
Suresh V. Ambudkar
Maria R. Baer
Publikationsdatum: 01.07.2007
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 2/2007
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-006-0357-8

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins